

DAFTAR PUSTAKA

- Abdulfatai, U., Uzairu, A., & Uba, S., 2016, Quantitative structure-activity relationship and molecular docking studies of a series of quinazolinonyl analogues as inhibitors of gammaamino butyric acid aminotransferase, *J. Adv. Res.* 8, doi:10.1016/j.jare.2016.10.004
- Ahmad, I., Yanuar, A., Mulia, K., & Mun'im, A., 2017, Review of Angiotensin-converting Enzyme Inhibitory Assay: Rapid Method in Drug Discovery of Herbal Plants, *Pharmacogn Rev.*, **11** (21): 1-7.
- Badan Litbangkes, 2018, *Laporan Nasional Riset Kesehatan Dasar (Riskesdas) 2018*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Bakris, G.L. & Sorrentino, M.J., 2018, *Hypertension: A Companion to Braunwald's Heart Disease*, 3rd Ed., 33-51, Elsevier Inc., Philadelphia.
- Bell, K., Twigg, J., & Olin, B.R., 2015, *Hypertension: The Silent Killer: Updated JNC-8 Guideline Recommendations*, 2-4, Alabama Pharmacy Association, Alabama.
- Bennet, V., 2007, xPharm: The Comprehensive Pharmacology Reference, *Elsevier*, 1-3.
- Carmel, A., Ehrlich-Rogozinsky, A., & Yaron, A., 1979, A Fluorometric Assay for Angiotensin-I Converting Enzyme In Human Serum, *Clinica Chimica Acta*, **93**: 215-220.
- CDC, 2021, High Blood Pressure Symptoms and Causes, <https://www.cdc.gov/bloodpressure/about.htm>, 7 Juni 2023.
- Cheng, Y.C. & Prusoff, W.H., 1973, Relationship Between The Inhibition Constant (K_i) and The Concentration of Inhibitor Which Causes 50 Percent Inhibition (I₅₀) of An Enzymatic Reaction, *Biochemical Pharmacology*, **22**: 3099-3108.
- Chin, W.W., 1998, The Partial Least Squares Approach to Structural Equation Modeling, *Modern Methods for Business Research*, 295-336.
- Cushman, D.W., Wang, F.L., Fung, W.C., Grover, G.J., Harvey, C.M., Scalese, R.J., Mitch, S.L., & DeForrest, J.M., 1989, Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE), *Br J Clin Pharmacol.*, **28** (2):115S-130S.
- Díaz-Gómez, J.L., Neundorff, I., López-Castillo, L-M., Castorena-Torres, F., Serna-Saldívar, S.O., & García-Lara, S., 2020, In Silico Analysis and In Vitro

Characterization of the Bioactive Profile of Three Novel Peptides Identified from 19 kDa α -Zein Sequences of Maize, *Molecules*, **25**: 5405.

- Dost, T., Kafkas, S., Gokalp, F., Karul, A., & Birincioglu, M., 2014, Effects of angiotensin converting enzyme inhibition on adiponectin levels and lipid profile in the ovariectomized-aged rats, *J Pharmacol Pharmacother.*, **5**: 21–26.
- Fang, L., Geng, M., Liu, C., Wang, J., Min, W., & Liu, J., 2019, Structural and molecular basis of angiotensin converting enzyme by computational modeling: Insights into the mechanisms of different inhibitors, *Plos One*, **14** (4): e0215609, <https://doi.org/10.1371/journal.pone.0215609>.
- Franklin, S.S. & Wong, N.D., 2013, Hypertension and Cardiovascular Disease: Contributions of The Framingham Heart Study, *Global Heart J.*, **8** (1): 49–57.
- Fountain, J.H., Kaur, J., & Lappin, S.L., 2023, Physiology, Renin Angiotensin System, <https://www.ncbi.nlm.nih.gov/books/NBK470410/>, 3 September 2023.
- Galli, C.L., Sensi, C., Fumagalli, A., Parravicini, C., Marinovich, M., & Eberini, I., 2014, A Computational Approach to Evaluate the Androgenic Affinity of Iprodione, Procymidone, Vinclozolin and Their Metabolites, *PLOS ONE*, **9**(8): e104822, <https://doi.org/10.1371/journal.pone.0104822>.
- Goyal, A., Cusick, A.S., & Thielemier, B., ACE Inhibitors, <https://www.ncbi.nlm.nih.gov/books/NBK430896/>, 5 September 2023.
- Hatcher, H., Planalp, R., Cho, J., Torti, F.M., & Torti, S.V., 2008, Curcumin: from ancient medicine to current clinical trials, *Cell Mol Life Sci*, **65**: 1631–1652.
- Hedge, M., Sosmitha, G., Bharathwaj Chetty, B., Vishwa, R., & Kunnumakkara, A. B., 2023, Better Bioavailability: What We Learned from Clinical Trials Thus Far?, *ACS Omega*, **8**: 10713–10746.
- Hevener, K.E., Zhao, W., Ball, D.M., Babaoglu, K., Qi, J., White, S.W., & Lee, R.E., 2009, Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase, *J. Chem. Inf. Model.*, **49**: 444–460.
- Jamwal, R., 2018, Bioavailable curcumin formulations: A review of pharmacokinetic studies in healthy volunteers, *J. Integr Med.*, **16** (6): 367–374.
- Jankun, J., Wyganowska, M., Dettlaff, K., Jelińska, A., Surdacka, A., Wątrbska-Świetlikowska, D., & Skrzypczak-Jankun, E., 2016, Determining whether

curcumin degradation/condensation is actually bioactivation (Review), *International Journal of Molecular Medicine*, **37**: 1151-1158.

- Kim, H.L, Kim, W.K., &Ha, A.W., 2019, Effects of Phytochemicals on Blood Pressure and Neuroprotection Mediated Via Brain Renin-Angiotensin System, *Nutrients*, **11** (11): 2761, doi: 10.3390/nu11112761.
- Kitchen, D.B., Decornez, H., Furr, J.R., &Bajorath, J., 2004, Docking and Scoring In Virtual Screening for Drug Discovery: Methods and Applications, *Nature Reviews*, **3**: 935-949.
- Kostis, W.J., Shetty, M., Chowdhury, Y.S., &Kostis, J.B., 2018, ACE Inhibitor-Induced Angioedema: a Review, *Current Hypertension Reports*, **20** (55), <https://doi.org/10.1007/s11906-018-0859-x>.
- Kunnumakkara, A.B., Harsha, C., Banik, K., Vikkurthi, R., Sailo, B.L., Bordoloi, D., Gupta, S.C., &Aggarwal, B.B., 2019, Is curcumin bioavailability a problem in humans: lessons from clinical trials, *Expert Opin Drug Metab Toxicol*, **15**(9): 705–733.
- Kusumawati, I.G.A.W., Putra, I.M.W.A., &Yogeswara, I.B.A., 2021, In Vitro ACE Inhibitory Activity and Bioactive Compounds of Aqueous Extract of *Citrus amblycarpa*, *Trad. Med. J.*, **26** (2): 118-122.
- Li, H.L., Liu, C., Couto, G.D., Ouzounian, M., Sun, M., Wang, A.B., Huang, Y., He, C.W., Shi, Y., Chen, X., *et al.*, 2008, Curcumin prevents and reverses murine cardiac hypertrophy, *J. Clin. Invest.*, **118**: 879–893.
- Marbun, P., Hakim, A., Ujiantari, N., Sudarmanto, B., &Nugroho, A., 2023, In silico Pharmacokinetics Study of 2,5-Dibenzylidenecyclopentanone Analogs as Mono-Ketone Versions of Curcumin, *BIO Web of Conferences*, **75**. 10.1051/bioconf/20237504002.
- Meiyanto, E., Nakamae, I., Kawaichi, M., Kato, J-Y., Lestari, B., Ikawati, M., Yoneda-Kato, N., Utomo, R., Jenie, R., Putri, H. &Larasati, Y., 2019, Anti-proliferative and Anti-metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation with ROS Generation, *Advanced Pharmaceutical Bulletin*, **9** (3): 445 452.
- Meiyanto, E., Putri, D.D.P., Susidarti, R.A., Murwanti, R., Sardjiman, Fitriasari, A., Husnaa, U., Purnomo, H. &Kawaichi, M., 2014, Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation, *Asian Pac. J. Cancer Prev.*, **15**: 179 184.

- Meng, X.Y., Zhang, H.X., Mezei, M., & Cui, M., 2011, Molecular docking: a powerful approach for structure-based drug discovery, *Curr Comput Aided Drug Des*, **7** (2): 146-57, doi: 10.2174/157340911795677602.
- MOE, 2015, Molecular Operating Environment, file:///D:/moe2015%20(2)/html/index.htm, 10 Maret 2024.
- Morris, G.M. & Lim-Wilby, M., 2008, Molecular docking, *Methods Mol Biol.*, **443**:365-82, doi: 10.1007/978-1-59745-177-2_19.
- Natesh, R., Schwanger, S.L.U., Sturrock, E.D., & Acharya, K.R., 2003, Crystal Structure of The Human Angiotensin-Converting Enzyme-Lisinopril Complex, *Nature*, **421**: 551-554, <https://doi.org/10.1038/nature01370>.
- Natesh, R., Schwanger, S.L.U., Sturrock, E.D., & Acharya, K.R., 2004, Structural Details on the Binding of Antihypertensive Drugs Captopril and Enalaprilat to Human Testicular Angiotensin I-Converting Enzyme, *Biochemistry*, **43**: 8718-8724.
- National Center for Biotechnology Information, 2024, PubChem Bioassay Record for AID 38859, Inhibitory activity against angiotensin I converting enzyme (ACE), <https://pubchem.ncbi.nlm.nih.gov/bioassay/39767>, 10 Maret 2024.
- National Center for Biotechnology Information, 2024, PubChem Bioassay Record for AID 39767, Inhibitory activity against angiotensin I converting enzyme (ACE), <https://pubchem.ncbi.nlm.nih.gov/bioassay/39767>, 10 Maret 2024.
- Ntai, I., & Bachmann, B.O., 2008, Identification of ACE pharmacophore in the phosphonopeptide metabolite K-26, *Bioorganic & medicinal chemistry letters*, **18** (10): 3068–3071, <https://doi.org/10.1016/j.bmcl.2007.11.130>.
- Pantsar, T. & Poso, A., 2018, Binding Affinity via Docking: Fact and Fiction, *Molecules*, **23**: 1899.
- Patrick, G.L., 2013, *An Introduction to Medicinal Chemistry*, 5th Ed., 5-11, Oxford University Press, Oxford.
- PERKI, 2015, *Pedoman Tatalaksana Hipertensi pada Penyakit Kardiovaskular*, 1-6, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Jakarta.
- PERKI, 2019, *Konsensus Penatalaksanaan Hipertensi*, 10-38, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Jakarta.
- Rachmawati, H., Soraya, I., S., Kurniati, N.F., & Rahma, A., 2016, In Vitro Study on Antihypertensive and Antihypercholesterolemic Effects of a Curcumin Nanoemulsion, *Scientia Pharmaceutica*, **84** (1): 131–140, doi: 10.3797/scipharm.ISP.2015.05.

- Ramírez, D. & Caballero, J., 2016, Is It Reliable to Use Common Molecular Docking Methods for Comparing the Binding Affinities of Enantiomer Pairs for Their Protein Target?, *Int J Mol Sci.*, **17** (4): 525.
- Ritmaleni, Fatmayanti, B.R., Ekananda, S.D., Tranggono, B.N., Arsani, N.K., & Rumiya, 2022, Synthesis and Antioxidant Activity of Some Dibenzylidene-Cyclohexanones, *Indonesian Journal of Pharmacy*, **34** (1): 93-102.
- Ritmaleni, Hastutitama, A.N.A., Persitamaia, I., Restiwardani, T., Eksakta, A., Munandar, R.F., Abdullah, M.S., Purwanto, A.E., Astuti, P., & Sardjiman, 2021, Synthesis and Antibacterial Activity of Fibenzylidene-cyclohexanone, *RASAYAN J. Chem.*, **14** (3): 2090-2096. doi: 10.31788/RJC.2021.1436240.
- Sardjiman, Reksohadiprodjo, M., Hakim, L., Van der Goot, H., & Timmerman, H., 1997, 1,5- Diphenyl-1,4-pentadiene-3-ones, and Cyclic Analogues as Antioxidative Agents: Synthesis and Structure-Activity Relationship, *Eur. J. Med. Chem.*, **32**: 625-630.
- Sentandreu, M.A. & Toldra, F., 2006, A fluorescence-based protocol for quantifying angiotensin-converting enzyme activity, *Nature Protocols*, **1** (5): 2423-2427.
- Stromgaard, K., Krogsgaard-Larsen, P., & Madsen, U., 2017, *Textbook of Drug Design and Discovery*, 21-28, CRC Press, Boca Raton.
- Sun, S., Xu, X., Sun, X., Zhang, X., Chen, X., & Xu, N., 2019, Preparation and Identification of ACE Inhibitory Peptides from the Marine Macroalga *Ulva intestinalis*, *Mar. Drugs*, **17** (3): 179.
- Sunagawa, Y., Morimoto, T., Wada, H., Takaya, T., Katanasaka, Y., Kawamura, T., Yanagi, S., Marui, A., Sakata, R., Shimatsu, A., Kimura, T., Kakeya, H., Fujita, M., & Hasegawa K., 2011, A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats, *Circ. J.*, **75**: 2151-2159.
- Susanto, J.P., 2015, Konsep Baru Renin Angiotensin System (RAS), *Cermin Dunia Kedokteran*, **42** (2): 102-105, doi: 10.55175/cdk.v42i2.1038.
- Susanto, S.E. & Wibowo, T.H., 2022, Effectiveness of Giving Deep Relaxation to Reduce Pain in Hypertension Patients in Edelweis Room Down, Kardinah Tegal Hospital, *Jurnal Inovasi Penelitian*, **3** (4): 5841-5846.
- Thakur, A., Kumar, A., Sharma, V., & Mehta, V., 2022, PIC50: An open source tool for interconversion of PIC50 values and IC50 for efficient data

representation and analysis, *BioRxiv*, **10** (15): 512366, <https://doi.org/10.1101/2022.10.15.512366>.

Vyas, A., Dandawate, P., Padhye, S., Ahmad, A., & Sarkar, F., 2013, Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties, *Curr Pharm Des.*, **19** (11): 2047–2069.

Wells, B.G., DiPiro, J.T., Schwinghammer, T.L., & DiPiro, C.V., 2015, *Pharmacotherapy Handbook*, 9th Ed., 87-101, McGraw-Hill Education, New York.

WHO, 2023, Hypertension, <https://www.who.int/news-room/fact-sheets/detail/hypertension>, 7 Juni 2023.

Wijianto, B., Ritmaleni, Purnomo, H., & Nurrochmad, A., 2020, Curcumin Mono-Carbonyl Analogs As Potent Antibacterial Compounds: Synthesis, Biological Evaluation And Docking Simulation Study, *RASAYAN J. Chem.*, **13** (2): 1153-1165. doi:10.31788/RJC.2020.1325554.

Wijianto, B., Ritmaleni, Purnomo, H., & Nurrochmad, A., 2020, In silico and in vitro anti-inflammatory evaluation of 2,6-bis-(3'-ethoxy, 4'-hydroxybenzylidene)-cyclohexanone, 2,6-bis-(3'-Bromo, 4'-methoxybenzylidene)-cyclohexanone, and 2,6-bis-(3',4'-dimethoxybenzylidene)-cyclohexanone, *Journal of Applied Pharmaceutical Science*, **10** (6): 99-106. doi: 10.7324/JAPS.2020.10613.

Wijianto, B., Ritmaleni, Purnomo, H., & Nurrochmad, A., 2020, Quantitative Structure Activity Relationship (QSAR) study and Biological evaluation on Mono-ketone analogs of Curcumin as Antioxidant, *Research J. Pharm. and Tech*, **13** (10): 4829-4835. doi: 10.5958/0974-360X.2020.00850.1.

Wright, J.M., Musini, V.M., & Gill, R., 2018, First-line drugs for hypertension, *The Cochrane database of systematic reviews*, **4** (4): CD001841.

Yao, Y., Wang, W., Li, M., Ren, H., Chen, C., Wang, J., Wang, W. E., Yang, J., & Zeng, C., 2016, Curcumin Exerts its Anti-hypertensive Effect by Down-regulating the AT1 Receptor in Vascular Smooth Muscle Cells, *Scientific Reports*, **6**: 25579, doi: 10.1038/srep25579.

Yates, C.J., Masuyer, G., Schwager, S.L.U., Mohd, A., Sturrock, E.D., & Acharya, K.R., 2014, Molecular and Thermodynamic Mechanisms of the Chloride Dependent Human Angiotensin-I Converting Enzyme (ACE), *J Biol Chem*, **289**: 1798, <https://doi.org/10.1074/jbc.M113.512335>.

Zhang, D.W., Fu, M., Gao, S.H., & Liu, J.L., 2013, Curcumin and Diabetes: A Systematic Review, *Evid Based Complement Alternat Med*, 636053.

- Zheng, W., Tian, E., Liu, Z., Zhou, C., Yang, P., Tian, K., Liao, W., Li, J., & Ren, C., 2022, Small Molecule Angiotensin Converting Enzyme Inhibitors: A Medicinal Chemistry Perspective, *Front. Pharmacol.*, **13**: 968104.
- Zhuang, X.D., Liao, L.Z., Dong, X.B., Hu, X., Du, Z.M., Liao, X.X., & Wang, L., 2016, Design, synthesis, and antihypertensive activity of curcumin-inspired compounds via ACE inhibition and vasodilation, along with a bioavailability study for possible benefit in cardiovascular diseases, *Dovepress*, **10**: 129–139.